What does the selection of TearExo Inc.'s 'NEXs Tokyo' for the DIVE course mean?

It means that TearExo Inc. has been selected for the 'DIVE' course, which is part of the startup support program operated by Tokyo Metropolitan Government. This selection aims to strengthen collaboration in the Greater Tokyo Area and expand service implementation.

What is the TearExo® method provided by TearExo Inc.?

The TearExo® method is a technology that can detect extracellular vesicles (exosomes) in tear fluid with high sensitivity, speed, and ease, and at a low cost, without any preprocessing. It is 100 to 1000 times more sensitive than conventional methods and is expected to be applied to early detection of diseases such as breast cancer.

What is the background of TearExo Inc.'s establishment?

TearExo Inc. was established in April 2022 as a startup from Kobe University, following the JST-START program.

What are the main business activities of TearExo Inc.?

TearExo Inc. conducts research, development, manufacturing, and sales of liquid biopsy using molecular recognition materials. Specifically, they offer breast awareness support services for corporations and breast cancer risk assessment services using tear fluid.

What are the future goals?

The future goals are to promote early detection and early treatment of cancer by expanding corporate services in the Greater Tokyo Area, developing co-creation partners, and creating opportunities for collaboration with companies and organizations, ultimately aiming to achieve a healthy society.

AI News NQ Analysis

Kobe University-originated startup TearExo selected for the NEXs Tokyo 'DIVE' acceleration course

NQ Score 81/100

N1 Content Completeness 9

AI Summary (NQ-processed)

TearExo, a startup originating from Kobe University, has been selected for the 'DIVE' acceleration course of 'NEXs Tokyo', a support program hosted by the Tokyo Metropolitan Government. The company provides breast cancer risk assessment services using its proprietary TearExo® method and aims to accelerate its business in the Tokyo metropolitan area.

AI Analysis

Frequently Asked Questions

Q: What does the selection of TearExo Inc.'s 'NEXs Tokyo' for the DIVE course mean?: A: It means that TearExo Inc. has been selected for the 'DIVE' course, which is part of the startup support program operated by Tokyo Metropolitan Government. This selection aims to strengthen collaboration in the Greater Tokyo Area and expand service implementation.
Q: What is the TearExo® method provided by TearExo Inc.?: A: The TearExo® method is a technology that can detect extracellular vesicles (exosomes) in tear fluid with high sensitivity, speed, and ease, and at a low cost, without any preprocessing. It is 100 to 1000 times more sensitive than conventional methods and is expected to be applied to early detection of diseases such as breast cancer.
Q: What is the background of TearExo Inc.'s establishment?: A: TearExo Inc. was established in April 2022 as a startup from Kobe University, following the JST-START program.
Q: What are the main business activities of TearExo Inc.?: A: TearExo Inc. conducts research, development, manufacturing, and sales of liquid biopsy using molecular recognition materials. Specifically, they offer breast awareness support services for corporations and breast cancer risk assessment services using tear fluid.
Q: What are the future goals?: A: The future goals are to promote early detection and early treatment of cancer by expanding corporate services in the Greater Tokyo Area, developing co-creation partners, and creating opportunities for collaboration with companies and organizations, ultimately aiming to achieve a healthy society.